Corporate Presentation J. B Chemicals & Pharmaceuticals+91-22-30451200 | [email protected] Corporate Presentation J.B.Chemicals & Pharmaceuticals

CorporatePresentation

J. B Chemicals & Pharmaceuticals+91-22-30451200 | [email protected] www.jbcpl.com

CorporatePresentation

J.B.Chemicals & Pharmaceuticals Ltd.www.jbcpl.com

2

J. B. Chemicals & Pharmaceuticals Ltd.

Forward Looking Statements

In this presentation we have disclosed forward looking information to enable investors to comprehend our prospects and take informed investment decisions.

This presentation and other statements, written and oral, that we periodically make contain forward looking statements that set out anticipated results based on the management’s plan and assumptions.

We have tried wherever possible to identify such statements by using words such as ‘anticipate’, ‘aims’ ‘estimate’, ‘expects’, ‘project’, ‘intends’, ‘plans’, ‘believes’, and words of similar substance in connection with any discussion of future performance. We cannot guarantee that these forward looking statements will be realized, although we believe we have been prudent in assumptions.

The achievement of results is subject to risks, uncertainties and even inaccurate assumptions. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Everybody should bear this in mind.

3


4


The name J. B. Chemicals & Pharmaceuticals Ltd. was christened after Mr. J. B. Mody who is the Chairman and founder of JBCPL

JBCPL is a leading and publicly traded pharmaceutical company in India

Leading by the vision and dynamism of Mr. J. B. Mody, a visionary and pioneer with an experience of over five decades in the pharmaceutical industry, the group has diversified into different sectors

Background

5


Incorporated in 1976 with an IPO in 1985

Listed on the BSE and NSE with a market cap of USD 110 million

Manufacturing facilities in Gujarat and Maharashtra for formulations and API

Subsidiary in South Africa and Russia

Total employee strength of 2900

Brief on JBCPL

6


R

s. in

cro

res

2012-13 Quarterly Revenues & Profits

Financial year: April 2012 – March 2013

7


2012-13 Quarterly Revenues & Profits

Financial year: April 2012 – March 2013

U

SD in

mill

ions

8


Annual Revenues & Profits

Rs.

in c

rore

s

* Divestment of Russia-CIS OTC business to J&J

9


Annual Revenues & Profits

USD

in m

illio

ns

* Divestment of Russia-CIS OTC business to J&J

10


Strategic Business Units

11


India

Prescription products

Domestic market estimated at about USD 11 billion and growing by about 18% as per ORG

JBCPL Ranked 35th (ORG) with 3 brands featuring in top 300 brands reported by ORG

JBCPL continued consolidation process during 2011-12, and adopted key brands focus marketing strategy

Top 4 therapeutic segments: Gastro-enterology, Cardiovascular, Pain management and Antibiotic

Acute segment contributes about 82% of total sales

Current field force: 1100 sales representatives

12


India

Growth Plan

JBCPL has placed increased concentration on domestic market for next level growth.

Increase in field force

New product introductions

JBCPL plans to increase field force to 1500 in 2012-13. This is aimed at strengthening rural market presence with strength increase in urban market too

13


Contrast Media – niche focus

Contrast Media Products

Caters to niche radio-diagnostic products used in CT Scan, MRI and

Cath Lab through 30 sales representatives

Iopamidol

Iohexol

Gadopentetate dimeglumine

Diatrizoate Meglumine

In-licensed a new Ultrasound Contrast Imagining product (Definity)

of Lantheus Medical Imaging Inc. from USA

14


Russia/Ukraine/CIS

Kazakhstan

KyrghyztanUzbekistan

Tajikistan

Turkmenistan

AzerbaijanArmenia

Georgia

Maldova Ukraine

ByelorussiaLithuaniaLatvia Estonia

Russia

Mongolia

15


Russia/Ukraine/CIS

Russian market is estimated to be about US $12 billion at retail level, growing by about 7% in value annually

JBCPL is ranked amongst the top Indian companies

Entered Russia in 1992

Offices in Russia/Ukraine and some CIS countries

16


Russia/Ukraine/CIS

Divested OTC portfolio to Johnson & Johnson in May 2011

Contract manufacturing for J&J for these OTC products

Prescription business continues through wholly owned subsidiary in Russia

17


Global

Contract Manufacturing and Product pipeline will increase to fuel growth

Activity wise breakup

18


Global

Top markets breakup

19


South Africa

In 2007, JBCPL has made strategic investment in Biotech Laboratories (Pty) Ltd., South Africa, a BEE marketing and sales, marketing and distribution company

Have 49% equity stake with preference shares to take it to 51%

Robust products pipeline to strengthen direct business with Biotech

20


Contract Manufacturing (Clear Focus)

Projects awarded by multinationals globally

More than 10 clients

Tailor made services for customers

Contract Manufacturing

21


Complete package

New Product development

Analytics services

Technology transfer

Regulatory support

Manufacturing

Contract Manufacturing

22


Lozenges, a JBCPL niche strength, has excellent scope in global market

Medicated and Herbal

We manufacture lozenges under our own brands and private label

Private label lozenges for leading UK/EU, South African, Australian and Canadian companies.

Lozenges

23


JBCPL manufactures 2 APIs

one of the largest manufacturer of Diclofenac Sodium (BP, EP, USP) and Nifedipine

API Business

24


Brands | Assets

Zecuf herbal Cough and Cold

Nicardia (Nifedipine) Anti-hypertensive

Metrogyl (Metronidazole) Anaerobicide

Rantac (Ranitidine) Anti-peptic ulcerant

Panum (Pantaprazole) Anti-peptic ulcerant

OF (Ofloxacin) Antibiotic

Dicloran (Diclofenac Sodium) NSAID

25


At Daman

Located at Kadaiya, Daman

Manufactures lozenges and tablets

Lozenges approved by:

UK MHRA

TGA Australia

MCC South Africa

FDB Ghana

Manufacturing Facilities

26


At Gujarat

Plant TI – 10

Located at Panoli

Manufactures tablets

Facility approved by

US FDA

UK MHRA

TGA Australia

MCC South Africa

INVIMA Colombia

Germany (EU-GMP)


27


At Gujarat

Plant IV -17

Located at Panoli

Manufactures injectables -

FFS, vials and ampoules

Facility approved by:

MCC South Africa

INVIMA Colombia


28


At Gujarat

Plant IV -14

Located at Panoli

Manufactures injectables,

ointments & cold rubs


MCC South Africa

NDA Uganda

Pharmacy Board Tanzania

INVIMA Colombia


29


At Gujarat

Plant L-6

Located at Panoli

Manufactures herbal liquids


30


At Gujarat

Plant D 9

Located at Panoli

Manufactures Diclofenac API


US FDA

Germany EU-GMP


31


At Gujarat

Plant UM 12

Located at Ankleshwar

Manufactures tablets and liquids


NDA - Uganda (Tablets & liquids)

Pharmacy Board - Tanzania (liquid)


32


Strategy

ANDA: Develop and manufacture products for USA market

Contract Manufacturing: Increase our customer base by providing quality products at cost effective prices

Russia marketing: Form JV/Partnerships for marketing

New Territories: Expand into newer territories through partnerships

Capacities: Enhance capacities in 2012-13 for ANDA and contract manufacturing

tablets

Injectables

Lozenges

Thank You

+91-22-30451200 | [email protected]

J.B.Chemicals & Pharmaceuticals Ltd.

Documents

Corporate Presentation J. B Chemicals & Pharmaceuticals+91-22-30451200 | [email protected] Corporate Presentation J.B.Chemicals & Pharmaceuticals